Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

CMML2AML: Machine-learning discovery of co-mutations predictive of blast transformation in chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3844.

https://doi.org/10.1182/blood-2025-3844

Published: 2025

Journal Articles

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

Ettaib El Marabti, Ghaith Abu-Zeinah, Christopher Famulare, Ellen Ritchie, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2025-2026

Published: 2025

Journal Articles

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Jason Gotlib, John Mascarenhas, Raajit Rampal, Abdulraheem Yacoub, Hongfei Li, Josu Santamaria, Molly Halloran, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2025-2051

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Naseema Gangat, Ayalew Tefferi, Prithviraj Bose, Elizabeth Hexner, Laura Michaelis, Aaron Gerds, Akriti Jain, Prioty Islam, Raajit Rampal, Ronan Swords, Moshe Talpaz, Kristen Pettit, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Anna Halpern

Blood (2025) 146 (Supplement 1): 2042.

https://doi.org/10.1182/blood-2025-2042

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Chi-Joan How, Gabriela Hobbs, Aaron Gerds, Andriy Derkach, Emily Burton, Aurora Duran, Katherine Kan, Michael Mauro, Brian Chernak, Tamanna Haque, Raajit Rampal

Blood (2025) 146 (Supplement 1): 5606.

https://doi.org/10.1182/blood-2025-5606

Published: 2025

Journal Articles

Leveraging real-world workshop insights for improving education design: Patient-centered care of myelofibrosis with JAK inhibitors

Kristen Rosenthal, John Mascarenhas, Raajit Rampal, Shara Pantry, Carley Yawn, Sarah Nisly, Jason Everly, Timothy Quill, Kevin Obholz

Blood (2025) 146 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2025-2871

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Andrew Kuykendall, Rupali Roy, Abdulraheem Yacoub, Marina Kremyanskaya, Aaron Gerds, Ronald Paquette, Jeanne Palmer, Kathryn Johnson, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Ashley Yu, Rami Komrokji, Raajit Rampal, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 483.

https://doi.org/10.1182/blood-2025-483

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Xiaoli Wang, Cing Siang Hu, Xiaoping Su, Raajit Rampal, Noushin Farnoud, Erin McGovern, Andrew Davis, Sophia Jiang, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman

Blood (2025) 146 (Supplement 1): 359.

https://doi.org/10.1182/blood-2025-359

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Journal Articles

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Jan Philipp Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Giuliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Ross Levine, Prithviraj Bose, Raajit Rampal

Blood (2025) 146 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2025-3814

Published: 2025

Journal Articles

Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo

Trinayan Kashyap, Christopher Walker, Andrea Ellero, John Mascarenhas, Raajit Rampal, Pankit Vachhani, Yair Levy, Zhanet Grudeva-Popova, Pietro Taverna

Blood (2025) 146 (Supplement 1): 5537.

https://doi.org/10.1182/blood-2025-5537

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Raajit Rampal, Prithviraj Bose, Vikas Gupta, Francesca Palandri, Shiyuan Zhang, Jessica Lim, Fulya Sen Nikitas, Tom (sizhu) Liu, Jasmine Sahni, Catherine Ellis, Dwaipayan Patnaik, Florian Heidel, Francesco Passamonti

Blood (2025) 146 (Supplement 1): 5579.

https://doi.org/10.1182/blood-2025-5579

Published: 2025

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CMML2AML: Machine-learning discovery of co-mutations predictive of blast transformation in chronic myelomonocytic leukemia

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Leveraging real-world workshop insights for improving education design: Patient-centered care of myelofibrosis with JAK inhibitors

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only